{"id":"NCT00224120","sponsor":"Watson Pharmaceuticals","briefTitle":"A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2006-05","completion":"2006-05","firstPosted":"2005-09-22","resultsPosted":"2009-12-03","lastUpdate":"2009-12-15"},"enrollment":462,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Silodosin","otherNames":["Rapaflo"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Silodosin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.","primaryOutcome":{"measure":"Measuring Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Silodosin","deltaMin":21.2,"sd":4.88},{"arm":"Placebo","deltaMin":21.2,"sd":4.92}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":42,"countries":["United States"]},"refs":{"pmids":["19371887","23234617","21135869"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":233},"commonTop":["Retrograde ejaculation","Dizziness","Diarrhoea","Nasopharyngitis","Orthostatic hypotension"]}}